c-KIT deletion ameliorates AD pathology and masitinib is a c-KIT inhibitor currently under clinical investigation as a potential target in neurodegeneration, neuroinflammation, and cognitive improvement in AD (Folch et al, 2015; Fagiani et al, 2020; Dubois et al, 2023). The gene discussed is KIT; the disease is Alzheimer disease.